Overview

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-19

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, multi-center study to evaluate the efficacy, safety, PK, PD, and immunogenicity of eculizumab in Chinese participants with refractory gMG. Approximately 15 participants will be enrolled in the study.

Phase:

PHASE3

Details

Lead Sponsor:

Alexion Pharmaceuticals, Inc.

Treatments:

eculizumab